| 
																	
																	
																		 Connection
 
																		 Co-Authors
																		
																	 
																		This is a "connection" page, showing publications co-authored by   Kavita Nair   and   Robert McQueen.    
																		
																	 
																			
																					
					
					
		
			
			
			|  | 
				
					|  | Connection Strength |  |  
					|  |   |  |  
					|  | 1.572 |  |  |  |  
		
		
			
				Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.	
				
				
					Score: 0.244
				
				DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.	
				
				
					Score: 0.221
				
				McQueen RB, Mendola ND, Jakab I, Bennett J, Nair KV, N?meth B, Inotai A, Kal? Z. Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods. Pharmacoecon Open. 2023 Mar; 7(2):217-228.	
				
				
					Score: 0.203
				
				McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017 Jun; 20(6):585-591.	
				
				
					Score: 0.137
				
				McQueen RB, Ghushchyan V, Olufade T, Sheehan JJ, Nair KV, Saseen JJ. Incremental increases in economic burden parallels cardiometabolic risk factors in the US. Diabetes Metab Syndr Obes. 2016; 9:233-41.	
				
				
					Score: 0.132
				
				McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72.	
				
				
					Score: 0.123
				
				McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Campbell JD. Frequency of Continuous Glucose Monitoring Use and Change in Hemoglobin A1C for Adults with Type 1 Diabetes in a Clinical Practice Setting. Endocr Pract. 2014 Oct; 20(10):1007-15.	
				
				
					Score: 0.116
				
				McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205.	
				
				
					Score: 0.110
				
				Page RL, Ghushchyan V, Allen RR, Roper L, Beck D, Jonathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drug Healthc Patient Saf. 2012; 4:67-74.	
				
				
					Score: 0.099
				
				McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011 Sep 14; 9:13.	
				
				
					Score: 0.094
				
				Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98.	
				
				
					Score: 0.092
				 | 
																	
																		
																			
																					       Connection Strength       
  The connection strength for concepts is the sum of the scores for each matching publication.    
 Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
 |